Company: GANX
Filing Date: 2025-10-14
Form Type: 8-K
Source: 0001104659-25-099343
Chunk: 0

Company: Gain Therapeutics, Inc.
Filing Date: 2025-10-14
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD

On October 14, 2025, Gain Therapeutics, Inc. (the
“ Company”) hosted a virtual key opinion leader (KOL) event, “Biomarkers, Clinical Endpoints, and the Path to Disease
Modification: Contextualizing the emerging data from GT-02287” featuring Key Opinion Leaders (KOLs), Karl Kieburtz, M. D.,
M. P. H., Professor of Neurology, University of Rochester and Kenneth Marek, M. D., President and Senior Scientist, Institute for Neurodegenerative
Disorders. The slide presentation presented at the event is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form
8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission,
and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“ Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific
reference in such filing.

Item 9.01 Financial Statements and Exhibits.